Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jazz Pharmaceuticals ( (JAZZ) ) has issued an announcement.
On October 23, 2025, Jazz Pharmaceuticals announced the appointment of Dr. Ted Love to its board of directors, effective December 1, 2025. Dr. Love will serve as a Class I director until the 2027 annual general meeting and will join the Audit and Science and Medicine Committees. Concurrently, Kenneth W. O’Keefe announced his retirement from the board, effective December 1, 2025, with no disputes influencing his decision.
The most recent analyst rating on (JAZZ) stock is a Buy with a $199.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.
Jazz Pharmaceuticals’ overall stock score reflects strong technical momentum and promising growth prospects highlighted in the earnings call. However, financial performance is hindered by profitability challenges and high leverage, while valuation concerns persist due to negative earnings. The company’s ability to navigate these challenges and capitalize on growth opportunities will be crucial for future performance.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
Jazz Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines, particularly in the areas of neuroscience and oncology.
Average Trading Volume: 744,968
Technical Sentiment Signal: Buy
Current Market Cap: $8.4B
See more insights into JAZZ stock on TipRanks’ Stock Analysis page.